Allurion Technologies, Inc. · OTC:ALUR
Allurion Technologies — SPAC Merger (February 2023)
47 slides from Allurion Technologies's SPAC merger presentation, Feb 10, 2023
Slide 1: Investor Presentation February 2023
© 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL Investor Presentation February 2023
Slide 2: We have one goal: End Obesity
We have one goal: End Obesity
Slide 3: Allurion Executive Team
Allurion Executive Team Shantanu Gaur, M.D. Co - Founder, CEO Founded Allurion in 2009 at Harvard Medical School Ram Chuttani, M.D. Chief Medical Officer 20+ years as Harvard professor and Director of Endoscopy at BIDMC. Over 100 original scientific articles Chris Geberth Chief Financial Officer 25+
Slide 4: Dr. Robert Langer Chairs Allurion's Scientific Advisory Board
Dr. Robert Langer Chairs Allurion’s Scientific Advisory Board © 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL 4 One of only 12 Institute Professors Co - Founder Inventor on over 1,300 patents in materials science and drug delivery Most cited engineer in history “Allurion has cl
Slide 5: Compute Health Management Team
Compute Health Management Team 5 © 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL Dr. Omar Ishrak Chairman, Director Industry leaders with significant experience operating, investing, and capital raising in public and private markets across various geographies Joshua Fink Co - C
Slide 6: Omar Ishrak is a Proven Leader Within the Healthcare Industry
Omar Ishrak is a Proven Leader Within the Healthcare Industry © 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL 50+ deals representing $60bn+ 45,000 90,000 2011 2020 Employees $16 $29 2011 2020 $40+ $150+ June 2011 February 2020 35+ 2011 2020 Revenue ($bn) Market Cap ($bn) Condit
Slide 7: The Medtronic-Allurion Potential Partnership Opportunity
Potential Win - Win Opportunity (1) The Medtronic - Allurion Potential Partnership Opportunity 7 © 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL Digital Platform Balloon Surgery Partnership to expand access for Allurion’s technology Incremental revenue opportunity for both comp
Slide 8: Illustrative Transaction Summary
Sources Uses Cash from Non - Redeeming Shareholders and PIPE (5) $45 Cash to Balance Sheet $70 Cash from Royalty Financing and Debt Refinancing $42 Estimated Transaction Fees $17 (6) Total $87 Total $87 Illustrative Transaction Summary 8 Allurion Technologies, a weight loss technology company, plans
Slide 9: Allurion Aims to Solve One of the Biggest Problems in Healthcare
Allurion Aims to Solve One of the Biggest Problems in Healthcare, is Growing at an Exceptional Rate, and is Nearing Several Multi - Billion Dollar Catalysts © 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL 9 1 Obesity is one of the biggest unmet medical needs in the world and CO
Slide 10: Allurion At-A-Glance
Allurion At - A - Glance $1 $3 $7 $13 $20 $38 $64 $100 $140 2016 2017 2018 2019 2020 2021 2022E 2023E 2024E Revenue ($M) 85% CAGR 10 107% 2016 - 21 Revenue CAGR 106% 2016 - 21 Balloons Sold CAGR 1M digital weigh - ins in 2021 10M+ digital weigh - ins by 2023 76% 2021 gross margin 82% 2024E gross mar
Slide 11: The Problem
The Problem Allurion PROGRAM
Slide 12: Billion Adults Globally with BMI 25+: Large Opportunity
2 Billion Adults Globally with BMI 25+: Large Opportunity in Existing and Future Markets Currently launched in 50+ countries that represent 40% of TAM Launching in 15 countries over next 2 years that represent 60% of TAM* Existing Markets UK Italy France Saudi Arabia UAE Canada Mexico Australia Indi
Slide 13: COVID Exacerbated Obesity and Put the Need for Digital Health in the Spotlight
COVID Exacerbated Obesity and Put the Need for Digital Health in the Spotlight Obesity Increased During the Pandemic Healthcare Went Digital © 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL 13 43% of adults surveyed self - reported weight gain during the pandemic 1 70% are conce
Slide 14: Why We Believe Other Weight Loss Innovations Fail
Why We Believe Other Weight Loss Innovations Fail 14 Poor Economics High Risks Poor Experience Limited Channels Flawed Go - To - Market Execution Bariatric surgery is estimated to be $15,000 out - of - pocket 2 Drugs are estimated to be $1,000 per month 3 Invasive procedures are inherently risky in
Slide 15: Significant Market Opportunity Exists for Allurion
Significant Market Opportunity Exists for Allurion Multiple future catalysts will further expand TAM: B2B Digital SaaS Product Adolescent indication X - Ray Free Placement 8 - month Balloon Total population in considered areas across 8 geographies Target ages (18 - 65) and target BMI (>27) Target ho
Slide 16: Our Solution
Our Solution Allurion PROGRAM
Slide 17: The Allurion Program Combines a Medical Device, Digital Therapeutic, and Behavior Change Program
The Allurion Program Combines a Revolutionary Medical Device, Cutting - Edge Digital Therapeutic, and Behavior Change Program 17 © 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL The Allurion ® Balloon The Allurion Virtual Care Suite “Honeymoon from Hunger” Behavior Change Progra
Slide 18: AI-Powered Experiences Aiming to Provide Superior Outcomes
AI - Powered Experiences Aiming to Provide Superior Outcomes © 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL 18 AI - Powered Behavior Change Telehealth Coaching Real - time Messaging High Weight Loss High Durability High Engagement Millions of data points collected AI - Powered
Slide 19: Allurion Patients Achieve Pounds of Life-Changing Weight Loss
Allurion Patients Achieve 30 Pounds of Life - Changing Weight Loss on Average and Keep 95% of it Off at 1 - Year Weight Loss Weight Maintenance Diabetes Remission 30 pounds at 4 months 29 pounds at 12 months 30 pounds with 1 balloon at 4 months 50 pounds with 2 balloons at 12 months - 1.5 HbA1c - 1.
Slide 20: The Allurion Balloon was Designed to be Safer than Alternatives
The Allurion Balloon was Designed to be Safer than Alternatives Patients Value Procedureless… …and Procedureless Should Lead to Fewer SAEs 3X more patients prefer Allurion over surgery 6X more patients prefer Allurion over products that require endoscopy and anesthesia 65% of patients cite fear of c
Slide 21: Business Model
Business Model Allurion PROGRAM
Slide 22: Our B2B2C Business Model is Designed to Create an Economic Win-Win-Win
Our B2B2C Business Model is Designed to Create an Economic Win - Win - Win For All Stakeholders by Leveraging Our Procedureless Experience 22 © 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL Premium Pricing that leverages innovation Industry - Top Gross Margin driven by high ASP
Slide 23: Our Business Model Creates a Powerful Flywheel Effect
We Believe Our Business Model Creates a Powerful Flywheel Effect 23 © 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL ~70% of our business comes from existing providers Higher demand leads to higher account productivity B2B success stories drive organic account acquisition Improv
Slide 24: Allurion is the Only Weight Loss Company that Does it All
> 10% Weight Loss* <1% Complications* Digital Experience Provider Profit Affordable We Believe Allurion is the Only Weight Loss Company that Does it All © 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL 24 *Products not compared in head - to - head trials.
Slide 25: Strong Competitive Moat Protects our Business and Raises Barrier to Entry
Strong Competitive Moat Protects our Business and Raises Barrier to Entry © 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL 25 40+ Patents and 10+ Years of Manufacturing Trade Secrets 50+ Regulatory Approvals Leader in Weight Loss, Safety, and Provider Economics Growing database
Slide 26: Future Opportunities
Future Opportunities Allurion PROGRAM
Slide 27: Our Strategy
Our 3 - Year Strategy © 2021 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL Expand revenues in existing markets Launch in new markets Expand our platform to engage patients for a lifetime 27 © 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL
Slide 28: Expand Revenues in Existing Markets
Expand Revenues in Existing Markets Even at 100% CAGR, our TAM is still untapped © 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL 28 80 - 200+% CAGR in top direct markets High growth across all regions globally <0.2% penetration rate globally Reaching 1% penetration in just exis
Slide 29: Expand Revenues in Existing Markets: Potential Upside Not in Projections
Expand Revenues in Existing Markets Potential upside opportunities not included in projections © 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL 29 B2B SaaS Product Adolescents Ultrasound Placement 8 - month Balloon +35% TAM Expand label for use below 18 years +10% TAM Remove nee
Slide 30: Anticipated Launches in High Potential New Markets
Anticipated Launches in High Potential New Markets* Future Market Openings Will Drive Continued Growth © 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL 30 700M 1.1B 1.3B 2021 2022 2023 2024+ 2 Billion 44 countries currently launched Source: Allurion Market Research. *Values deno
Slide 31: IDE for AUDACITY Trial Has Been Approved by FDA
IDE for AUDACITY Trial Has Been Approved by FDA Enrollment begun in May 2022 © 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL Balloon 2 Break Balloon 1 Break Moderate Intensity Lifestyle Therapy Moderate Intensity Lifestyle Therapy W0 W16 W24 W40 W48 Treatment Group ( n = 250) C
Slide 32: Sequential Use of Allurion Balloon
Sequential Use of Allurion Balloon In a study of 42 patients, sequential balloon use led to an average weight loss of 22kg at 1 - year 32 % Total Body Weight Loss 0.0 - 5.0 - 15.0 - 20.0 - 25.0 - 30.0 - 10.0 Balloon #1 Balloon #2 - 14% - 10% +2% - 23% % Total Body Weight Loss Break © 2023 ALLURION T
Slide 33: The AUDACITY Trial Design Reflects FDA's Updated Recommendations
The AUDACITY Trial Design Reflects FDA’s Updated Recommendations for Weight Loss Devices and Builds Upon the ENLIGHTEN Trial 33 Pre - FDA White Paper Post - FDA White Paper © 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL The ENLIGHTEN Trial IDE approved in 2016, Read - out in 2
Slide 34: Digital Front Door + Infinite Corridor
Digital Front Door + Infinite Corridor Allurion is Building a Full - Stack Weight Loss Platform 34 Overweight BMI 25 - 30 1.25B people Obesity BMI 30 - 40 590M people Severe Obesity BMI 40+ 60M people APP SCALE TRACKER BEHAVIOR CHANGE PROGRAM Procedureless Interventions BALLOON MEDICATION FOOD Surge
Slide 35: Financial Overview
Financial Overview Allurion PROGRAM
Slide 36: We Believe Further Investment Should Lead to Continued Strong Growth
2020 2021 2022E 2023E 2024E $3 $7 2017 2018 2019 $13 $20 $38 $64 $100 85% CAGR Strong management track record of delivering high growth and beating internal forecast in each of last 5 years 85% revenue CAGR through 2024 80%+ gross margins in 2024 Potential revenue upsides not included: We Believe Fu
Slide 37: Financial Summary
Financial Summary 37 ($ in Millions) 2021 2022E 2023E 2024E Revenue $38 $64 $100 $140 % Growth 87% 68% 56% 40% ( - ) Cost of Goods Sold $(9) $(14) $(20) $(25) Gross Profit $29 $50 $80 $115 % Margin 76% 78% 80% 82% ( - ) S&M $(25) $(50) $(60) $(70) Operating Income $(12) $(32) $(29) $1 % Margin (32%)
Slide 38: Use of Proceeds Focused on Commercial Growth
Use of Proceeds Focused on Commercial Growth © 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL 38 Drive top line revenue through investment in sales and marketing Execute clinical trials for regulatory approvals and label expansion Launch digital B2B SaaS model Expand manufacturi
Slide 39: Investment Highlights
Investment Highlights 39 © 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL 1 Large Addressable Market with COVID - 19 Tailwinds 3 Core Business Growing at a 100%+ CAGR with Clear Path to 80%+ Margins 4 Superior, Clinically and Commercially Proven, Tech - Enabled, Disruptive Innov
Slide 40: Appendix
Appendix Allurion PROGRAM
Slide 41: Fully Diluted Ownership at Close
Fully Diluted Ownership at Close Share Ownership ≤ $ 10.00 $11.00 $12.00 $13.00 $14.00 $15.00 $16.00 $17.00 $18.00 $19.00 $20.00 Rollover Equity Shares (3) 38.312 38.312 38.312 38.312 38.312 38.312 38.312 38.312 38.312 38.312 38.312 Seller Earnout Equity Shares – – – – – 4.500 4.500 4.500 4.500 4.50
Slide 42: Disclaimer About This Presentation
Disclaimer About This Presentation This confidential investor presentation (together with the oral statements made in connection herewith, the “Presentation”) contains proprietary and confidential information of Allurion Technologies Holdings, Inc. (“Pubco”), Compute Health Acquisition Corp. (“Compu
Slide 43: Disclaimer (cont'd)
Disclaimer (cont’d) Financial Data and Use of Projections The financial information and operating metrics contained in this Presentation are unaudited and do not conform to Regulation S - X. Such information and data may not be included in, may be adjusted in or may be presented differently in, the
Slide 44: Risk Factors
Certain factors may have a material adverse effect on our business, financial condition and results of operations. The risks and uncertainties described below are not the only ones we face. Additional risks that we are unaware of, or that we currently believe are not material, may also become import
Slide 45: Risk Factors (cont'd)
Risk Factors (cont’d) © 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL • We have a significant amount of debt, which may affect our ability to operate our business and secure additional financing in the future. • From time to time, we engage outside parties to perform services r
Slide 46: Transaction Risks
Transaction Risks © 2023 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL • The ability of Compute Health’s public shareholders to exercise redemption rights may adversely affect our liquidity and capital resources. • The Company and Compute Health will be subject to business uncertain
Slide 47: Allurion
Allurion